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AbsTrACT
Objective To evaluate the rate of neointimal 
development and thrombus formation of surface-
modified flow diverters in single antiplatelet therapy 
(saPT) using optical coherence tomography (OcT) in a 
porcine model.
Methods We divided 10 experimental pigs into two 
groups. One group (n=6) received dual antiplatelet 
therapy (DaPT) and the other group (n=4) received 
saPT. Four stents (two per carotid artery) were implanted 
in both groups. The stents used were the Pipeline Flex 
embolization device (PeD Flex), Pipeline Flex with 
shield technology (PeD shield), and the solitaire aB 
stent. all animals underwent weekly angiography and 
OcT. The OcT data were analyzed using the following 
measurements: neointimal ratio ((stent – lumen area)/
stent area), stent-coverage ratio (number of stent struts 
covered by neointima/total stent struts), and the presence 
or absence of thrombus formation per 1 mm cross-
section.
results PeD Flex and shield in the saPT group 
had higher neointimal ratios than in the DaPT group 
(P<0.001, respectively). in the DaPT group, the speed 
of endothelial growth on day 7 in the PeD shield group 
was higher than that in the PeD Flex group (P<0.001). 
in the saPT group, PeD Flex demonstrated significantly 
more thrombus formation on day 7 than PeD shield 
(P<0.001).
Conclusions The PeD shield stent showed faster 
endothelial growth than the other devices and 
comparable neointimal volume. There was significantly 
less thrombus formation on PeD shield than PeD Flex 
when using saPT in a porcine model.
INTrODuCTION
While flow diverters can introduce thromboembolic 
complications when used to treat intracranial aneu-
rysms,1–3 a phosphorylcholine (PC) surface-mod-
ified flow diverter can be introduced to decrease 
thrombogenicity. PC is present on the surface 
of red blood cells. Recently, Medtronic (Irvine, 
Calfornia, USA) developed a version of its popular 
Pipeline Flex embolization device (PED Flex) that 
is modified with PC (PED Shield), with the intent 
of decreasing platelet adhesion to the implant by 
mimicking the surface of red blood cells.4 Indeed, 
platelet adherence and thrombosis have been 
shown to be inhibited on such PC-coated stents 
when placed in the peripheral arteries of rabbits, 
pigs, dogs, and baboons.5–9 Moreover, PC-coated 
stents have demonstrated no adverse effect on 
endothelialization.5–7
Dual antiplatelet therapy (DAPT) prior to 
implanting flow diverters is recommended to 
prevent thrombotic complications. However, 
delayed hemorrhagic complication still remains a 
concern with this modality. Although Hagen et al 
reported that the PED Shield with acetylsalicylic 
acid (ASA) alone exhibited similar platelet depo-
sition to the PED Flex with DAPT ex vivo,10 it is 
unclear whether PC surface-modified stents require 
less antiplatelet therapy than currently recom-
mended in vivo.10 11
Optical coherence tomography (OCT) is an intra-
vascular high-definition imaging method that allows 
for in vivo tracking of neointima and thrombus 
development on the surface of an implanted device. 
A number of reports have validated the correlation 
of OCT imaging and histology of the coronary 
arteries.12 13 Furthermore, we reported a correla-
tion for the development of neointima between 
OCT images and the histology of the carotid artery 
in a porcine model.14
We hypothesized that single antiplatelet therapy 
(SAPT) might be safely applied to PC surface-mod-
ified flow diverters. We evaluated and compared 
the rate of neointimal development and thrombus 
formation between standard and surface-modified 
flow diverters receiving SAPT and DAPT.
MeThODs
The study protocol was approved by the local 
institutional Animal Care and Use Committee. All 
animals received humane care in compliance with 
the Animal Welfare Act and the ‘Guide for the Care 
and Use of Laboratory Animals’ formulated by the 
Institute of Laboratory Animal Research (National 
Research Press, 1996).
We divided the 10 animals into two groups based 
on the antiplatelet protocol—namely, DAPT (n=6) 
and SAPT (n=4). The animals were Yorkshire 
pigs ranging in size from 10 to 35 kg. Both groups 
started antiplatelet therapy 3 days prior to stenting. 
The DAPT group received ASA (10 mg/kg) and 
clopidogrel (10 mg/kg). The SAPT group received 
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Figure 1 Optical coherence tomography imaging. (A) Green and purple circles show the lumen area and stent area, respectively. (B) Stent strut 
classification is defined from types 1–4 by OCT imaging. Types 1 and 2 are uncovered struts and types 3 and 4 are covered struts (red circle).14
only ASA (10 mg/kg), as in a previously reported trial.14 The 
implanted device sizes were 5×20 mm and 5×12 mm for PEDs 
and 4×20 mm and 5×20 mm for Solitaire AB, with two of the 
same kind of device implanted in each carotid artery. All inter-
ventions were performed under general anesthesia. Induction of 
anesthesia was achieved with subcutaneous tiletamine (4.4 mg/
kg), xylazine (2.2 mg/kg), and atropine (0.4/mg/kg). After intu-
bation we maintained isoflurane inhalation anesthesia (1.5–3%). 
The procedure started with a sterile cut-down to the femoral 
artery and placement of a 6F femoral sheath or percutaneously 
placed sheath. After sheath insertion, heparin (3000–8000 U) 
was administered. A 6F guide catheter was navigated to obtain 
baseline angiography and measurements. We used a 0.027 inch 
microcatheter to deploy the devices. PED Flex, PED Shield, and 
Solitaire AB were randomized for implantation into the bilat-
eral carotid arteries with four stents in each experimental pig, 
with one exception with two stents because of anatomical diffi-
culty. After the procedure the animals stayed under observation 
until fully recovered. All animals from both groups underwent 
follow-up angiograms and intravascular imaging with optical 
coherence tomography (OCT) at three time points (days 7, 14, 
and 21). During the study we lost one animal from the DAPT 
group due to an anesthesia complication; follow-up was not 
possible for this subject.
OCT imaging and analysis
OCT images were obtained using the Dragonfly Optis imaging 
system (LightLab Imaging, St Jude Medical, Minnesota, USA). In 
this procedure the OCT catheter is introduced into the 6F guide 
catheter and advanced over a 0.014 inch microguidewire distal 
to the implanted stents. A motorized OCT catheter pull-back 
at a rate of 18.0 mm/s and a simultaneous intra-arterial iodine 
contrast injection at rates of 4–6 mL/s for a total volume of 
16–24 mL to clear the blood from the vessel were used to obtain 
all OCT images at 180 frames/s.
Follow-up digital subtraction angiography and OCT imaging 
were performed at three time points (days 7, 14, and 21). OCT 
image analysis was performed with Light Lab post-processing 
software. Every 1 mm of the OCT image dataset was analyzed. 
The measurements involved an automated device contour 
detection algorithm and endoluminal surface detection. Stent 
struts were manually traced and regions of interest were posi-
tioned in the center of the stent struts that showed a bright 
'blooming' appearance (figure 1A).3 The following parameters 
were measured (figure 1A)14: lumen area (defined as contours of 
the vessel lumen), stent area (identified by circumferential area 
limited by the contours of the struts), neointimal area (stent area 
– lumen area), and neointimal ratio ((mean stent – mean lumen 
area)/mean stent area). OCT imaging was used to classify stent 
struts as types 1–4, with types 1 and 2 defined as uncovered struts 
(no neointima) and types 3 and 4 as covered struts (figure 1B).15 
The stent-coverage ratio was measured as the number of stent 
struts covered by neointima/total stent struts. The neointimal 
ratio was a marker for neointimal volume, with a higher neoin-
timal ratio indicating more neointimal formation. Change in the 
stent-coverage ratio over time showed the speed of endotheliali-
zation of the stent struts.
Red thrombus was defined by images showing protrusions 
into the lumen with high OCT backscattering and attenuation 
while white thrombus was defined by homogeneous backscat-
tering and low attenuation.16 Thrombus formation was defined 
as present or absent in every 1 mm cross-section. OCT images 
were excluded from the analysis if stent struts and lumen contour 
were not visible in more than 45 degrees.
All pigs were euthanized under deep anesthesia with a lethal 
dose of potassium chloride on day 21 after the procedure. The 
vessels with stents were submitted for histology.
OCT data were analyzed by YM, DKJ, and JC.
statistical analysis
All data are presented as mean±SD. Differences in parametric 
data were evaluated using a one-way analysis of variance. The 
Tukey test was used as a post hoc analysis. Non-parametric data 
between two groups were evaluated by the Mann–Whitney 
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Neointimal ratio on day 21
  SAPT 0.21±0.16* 0.22±0.11* 0.044±0.12 NS <0.001 <0.001
  DAPT 0.087±0.10 0.095±0.063 0.023±0.012 NS <0.001 <0.001
  Total 0.12±0.13 0.13±0.098 0.032±0.081 NS <0.05 <0.05
Stent-coverage ratio on day 7
  SAPT 0.82±0.24* 0.79±0.24* 0.78±0.22 NS NS NS
  DAPT 0.32±0.28 0.59±0.36 0.81±0.22 <0.001 <0.001 <0.001
Stent-coverage ratio on day 14
  SAPT 0.93±0.096 0.92±0.13 0.81±0.28 NS NS NS
  DAPT 0.92±0.093 0.93±0.13 0.90±0.16 <0.001 NS 0.031
Stent-coverage ratio on day 21
  SAPT 0.96±0.10* 0.98±0.059* 0.85±0.27 NS 0.011 NS
  DAPT 0.88±0.15 0.93±0.12 0.86±0.18 0.002 NS NS
%Thrombus formation on day 7
  SAPT 100±0.00* 36.36±48.38* 43.08±49.90 <0.001 NS <0.001
  DAPT 9.42±29.32 9.40±29.28 33.33±47.35 ns <0.001 <0.001
  Total 39.02±48.90 19.41±39.63 36.93±48.40 <0.001 <0.001 NS
*P<0.001 compared with DAPT.
DAPT, dual antiplatelet therapy; Flex, Pipeline Flex embolization device; SAPT, single antiplatelet therapy; Shield, Pipeline Flex embolization with Shield technology. 
Figure 2 Neointimal ratios on day 21. The PED Flex and Shield 
showed a significant difference between the SAPT and DAPT protocols. 
For both protocols, Solitaire demonstrated significantly lower neointimal 
ratios than PED Flex and Shield. Bars are 95% CI. PED Flex, Pipeline Flex 
embolization device; PED Shield, Pipeline Flex embolization with Shield 
technology; SAPT, single antiplatelet therapy; DAPT, dual antiplatelet 
therapy; Flex, PED Flex; Shield, PED Shield; *P<0.001 compared with 
DAPT; †P<0.001 compared with PED Flex; ‡P< 0.001 compared with 
PED Shield.
U test, and those among three groups by the Kruskal–Wallis 
test. The Bonferroni correction for multiple comparisons was 
performed. SPSS Version 23 (IBM, Armonk, New York, USA) 
was used for statistical analysis.
resulTs
The first angiographic follow-up demonstrated a high rate of 
stent thrombosis for the SAPT group; 6/6 of the PED Flex and 
2/6 of PED Shield were occluded. All thrombosed devices under-
went successful recanalization after mechanical thrombectomy 
with aspiration and angioplasty using a non-compliant balloon.14 
We decided to amend the protocol and start DAPT for all exper-
imental pigs after the eighth day follow-up results. Thereafter, 
ASA was administered daily throughout the study in all animals, 
and 10 mg/kg of clopidogrel was administered after the initial 
follow-up demonstrating 100% thrombosis of the SAPT group 
of PED Flex. Subsequent follow-up angiography showed no 
further implant thrombosis. The number of stents obtained by 
OCT images were seven PED Flex, seven PED Shield, and four 
Solitaire AB in the DAPT group, and six PED Flex, six PED 
Shield, and four Solitaire AB in the SAPT group. A total of 2348 
slices on OCT images were evaluated.
Neointimal ratio
The results for the neointimal ratio on day 21 are shown in 
table 1 and figure 2. The neointimal ratios for the PED Shield 
and Flex were significantly different from that for Solitaire in 
both antiplatelet groups (neointimal ratio±SD: PED Flex and 
Shield vs Solitaire in SAPT and DAPT group, P<0.001, respec-
tively; in total group, P<0.05). The neointimal ratio for PED 
Shield and Flex was similar in the combined groups. PED Flex 
and Shield stents showed a significantly higher neointimal ratio 
in the SAPT group than in the DAPT group (P<0.001, respec-
tively). We found no difference in the neointimal ratio for the 
Solitaire stent between the SAPT and DAPT groups (P=0.126).
stent-coverage ratio
Results for the stent-coverage ratio are shown in table 1 and 
figure 3. In the DAPT group, PED Shield showed a greater 
stent-coverage ratio than Flex at every follow-up time point 
(table 1, figure 3: day 7, P<0.001; day 14, P<0.001; day 21, 
P=0.002). In the SAPT group we found no difference between 
the PED Flex and Solitaire group at any follow-up time point. 
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Figure 3 Stent-coverage ratio over time. For the DAPT protocol, PED 
Shield showed a significantly higher stent-coverage ratio than PED 
Flex. In the SAPT group there was no difference between PED Shield 
and PED Flex at any time point. PED Shield in the SAPT group showed 
significantly more endothelialization than Solitaire on day 21. PED 
Flex and Shield both showed higher stent-coverage ratios for the SAPT 
protocol than the DAPT protocol. PED Flex, Pipeline Flex embolization 
device; PED Shield, Pipeline Flex embolization with Shield technology; 
SAPT, single antiplatelet therapy; DAPT, dual antiplatelet therapy; Flex, 
PED Flex; Shield, PED Shield.
Figure 4 Thrombus formation percentage on day 7. In the SAPT 
protocol, PED Flex showed thrombus for all frames on day 7. In 
addition, PED Flex showed more thrombus formation than PED Shield 
and Solitaire. On the other hand, we found no difference in thrombus 
formation between PED Shield and the Solitaire stent in the SAPT 
protocol. In the DAPT protocol, Solitaire showed significantly more 
thrombus formation than PED Flex or Shield. Bars are 95% CI. PED Flex, 
Pipeline Flex embolization device; PED Shield, Pipeline Flex embolization 
with Shield technology; SAPT, single antiplatelet therapy; DAPT, dual 
antiplatelet therapy; Flex, PED Flex; Shield, PED Shield. *P<0.05 
compared with DAPT; †P<0.05 compared with PED Flex; ‡P<0.05 
compared with Solitaire.Although there was no difference in the stent-coverage ratio on 
day 7 between the SAPT PED Shield and the Solitaire group, this 
ratio on day 21 was significantly increased in the PED Shield 
group compared with the Solitaire group (P=0.011).
The stent-coverage ratio for PED Flex and Shield was signifi-
cantly higher in the SAPT group than in the DAPT group on 
days 7 and 21 (day 7, P<0.001, respectively; day 21, P<0.001, 
respectively). There was no difference in the stent-coverage ratio 
between the DAPT and SAPT groups at any time in the follow-up 
period for the Solitaire stent (day 7, P=0.381; day 14, P=0.196; 
day 21, P=0.312). Regarding endothelial formation, all devices 
were almost completely covered by day 21.
Thrombus formation
The results of thrombus formation on the surface of the stent 
on day 7 are shown in table 1 and figure 4. In the SAPT group, 
PED Flex showed thrombus for all frames on day 7. In addition, 
PED Flex showed more thrombus formation than PED Shield 
or Solitaire (P<0.001, P<0.001). On the other hand, we found 
no difference for thrombus formation between the PED Shield 
and Solitaire stents in the SAPT group. In the DAPT group, Soli-
taire showed significantly more thrombus formation than PED 
Flex or Shield (P<0.001, P<0.001). When considering both 
DAPT and SAPT, the percentage of thrombus formation on the 
surface of the PED Shield was lower than for the other devices 
(P<0.001, P<0.001).
DIsCussION
Our study showed that the PED Shield stent had faster endo-
thelial growth and less thrombus formation than PED Flex and 
Solitaire.
speed of stent-coverage
In the literature there are reports proposing that coronary 
PC-coated stents might reduce the rate of re-endothelialization 
because of inhibition of the deposition of plasma protein onto 
the stent strut.8 17 However, in the DAPT group we found a 
significant difference in the stent-coverage ratio for PED Shield 
compared with PED Flex at each time point of our follow-up 
until the device was fully covered with neointima. These results 
could support the notion that the PC effect induces faster endo-
thelialization. On the other hand, in the SAPT group there was 
no difference in the stent-coverage ratio on day 7 between the 
PED Shield and the Flex and Solitaire groups. In fact, on day 21 
the PED Shield showed more endothelial coverage than Solitaire. 
These results also suggest that the PED Shield, which has PC 
surface modification, accelerated the endothelialization process 
compared with the other devices studied in this porcine model. 
This result must be further investigated since surface modifi-
cation could be less thrombogenic immediately after implanta-
tion and may also shorten the duration of antiplatelet therapy 
needed, since complete endothelialization of the device is seen at 
a significantly earlier time than with the other devices tested. As 
a result, the PED Shield stent may allow us to discontinue anti-
platelet therapy sooner than the current practice and decrease 
the impact of antiplatelet therapy complications. Additionally, 
our study also supports previous reports that early endotheliali-
zation of the PED Shield reduces the risk of thrombus formation 
after implantation.18
Neointimal volume
In coronary lesions, excessive neointimal hyperplasia leads to 
in-stent restenosis.19 We used the neointimal ratio as the index 
of neointimal volume.14 PED Shield demonstrated no difference 
for neointimal volume compared with PED Flex in the DAPT 
and SAPT groups. This finding suggests that PC surface modi-
fication results in similar rates of in-stent stenosis or late loss 
between PED Flex and Shield. However, Caroff et al reported 
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Figure 5 Representative OCT image (left) and histopathological findings (right) in Pipeline Flex embolization device demonstrating the correlation 
between the two techniques. Left: OCT image shows thrombus on the surface of the stent (red square). Right: Thrombus covered by neointima was 
shown on magnification (black arrows) in histopathological finding. OCT, optical coherence tomography.
that a surface-modified flow diverter had significantly less 
in-stent neointimal hyperplasia in a rabbit model.20 The differ-
ence in animal model might cause the difference between their 
result and ours.
Darsaut et al reported that aneurysm occlusion was associ-
ated with neointimal closure of the flow diverter pores and the 
amount of metal surface coverage over the aneurysm ostium.21 
We found a significant difference in the neointimal volume 
between the flow diverter and Solitaire stent in both the SAPT 
and DAPT groups. The more significant neointimal volume seen 
in flow diverters during this study may be one of the reasons we 
see more durable aneurysm occlusion rates with PED Flex and 
Shield than with Solitaire (lower coverage devices).
Thrombus formation
Some previous studies have reported that platelet adhesion 
and thrombus are reduced in PC-coated devices.5–8 Our study 
demonstrated that PED Shield was less thrombogenic than PED 
Flex in the SAPT group. In addition, in the SAPT group, PED 
Shield was similar to Solitaire in terms of thrombogenicity, as 
reported previously.22 Hagen et al reported that PED Shield 
with aspirin showed similar thrombogenicity to PED Flex under 
DAPT.10 In a rabbit model, Marosfoi et al reported that PED 
Shield was associated with less thrombus formation regardless of 
antiplatelet therapy.9 Our protocol was changed mid-experiment 
because of the high rate of thrombosis in PED Flex in the SAPT 
group. We therefore evaluated thrombus formation on day 7 
before switching to the DAPT protocol. In our study, PED Shield 
demonstrated a higher rate of thrombus in the SAPT group 
compared with PED Flex under DAPT (36.36% vs 9.42%). 
Based on this animal study, the use of PED Shield with SAPT 
should still be carefully considered. However, in ruptured cases 
in whom DAPT or additional surgery such as external ventricular 
drainage is difficult to administer and shunt placement is neces-
sary, PED Shield could be more feasible than PED Flex.
There are some reports describing an association of thrombus 
and neointima. The intimal thickening consisted of organizing 
thrombus.8 Moreover, early thrombus formation and acute 
inflammation was followed by neointimal growth after bare 
metal stent implantation.23 24 Our histology showed thrombus 
covered by neointima in figure 5. In this study, the neointimal 
volume of the flow diverter was greater in the SAPT group 
than in the DAPT group. Furthermore, both flow diverters in 
our results showed a greater stent-coverage ratio at day 7 in the 
SAPT protocol than in the DAPT protocol. Thrombus could 
result in more endothelialization. Therefore, these results indi-
cate that thrombus could induce the development of neointimal 
formation.
study limitations
We recognize that this study and its conclusions may have limita-
tions and the translation to clinical practice needs to be carefully 
considered.
The high rate of thrombosis in the SAPT group caused changes 
in the antiplatelet therapy protocol and mechanical throm-
bectomy for recanalization of thrombosed stents. Mechanical 
thrombectomy for thrombosed PED Flex and Shield could influ-
ence endothelialization. Steele et al reported that percutaneous 
transluminal angioplasty (PTA) could result in endothelial denu-
dation in vessels, followed by complete endothelial regrowth 
7 days after PTA.25 Considering this report, the effect of PTA 
could hardly impact our stent-coverage ratio on day 7 because 
the measurement for OCT images was performed just after PTA. 
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The follow-up period of our study was just 1 month. Late 
in-stent restenosis might show different results in long-term 
follow-up. However, our previous report demonstrated that 
the concentric neointima in the PED Shield might reduce late 
in-stent restenosis.14 In addition, this study had few subjects; a 
larger and longer cohort study is necessary to prove the effect 
of PC-coated flow diverters. Another limitation is the potential 
biases of OCT image evaluation of different observers.
CONClusIONs
This study used OCT to compare endothelial development in 
different neurovascular implants in vivo. The PED Shield stent 
showed faster endothelial growth than the other devices and 
comparable neointimal volume. We observed no difference in 
thrombus formation on the surface of flow diverters when using 
DAPT. On the other hand, there was significantly less thrombus 
formation for the surface-modified flow diverter (PED Shield) 
compared with PED Flex when using SAPT in a porcine model.
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